<DOC>
	<DOCNO>NCT00430677</DOCNO>
	<brief_summary>The purpose clinical research study learn addition abatacept safe improves effectiveness treatment patient active lupus nephritis also take mycophenolate mofetil ( MMF ) corticosteroid .</brief_summary>
	<brief_title>Efficacy Safety Study Abatacept Treat Lupus Nephritis</brief_title>
	<detailed_description>Double Blind Period : Treatment , Parallel Assignment , Double Blind ( Subject , Investigator ) , Randomized , Active Control , Safety/Efficacy Study Open Label Period : Prevention , Single Group Assignment , Open Label , Uncontrolled , Safety/Efficacy Study</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>Systemic Lupus Erythematosus ( SLE ) define meet least 4 11 classification criterion American College Rheumatology classification Systemic Lupus Erythematosus , either sequentially coincident . The 4 criterion need present study entry Renal biopsy within 12 month prior screen visit indicate active proliferative lupus glomerulonephritis ( meet ISN/RPS Class III IV classification criterion [ 2003 ] , exclude Class III [ C ] , IVS [ C ] IVG [ C ] , World Health Organization Class III IV classification criterion [ 1982 ] , exclude Class IIIc , IVd ) . If renal biopsy perform &gt; 3 month ≤12 month prior screen visit , least 1 follow 3 serology ( perform locally ) must abnormal prior screen visit : complement ( C3 C4 ) level normal range OR antidsDNA &gt; upper limit normal range . A stable serum creatinine ≤3 mg/dL Subjects rise serum creatinine ≥1 mg/dL within 1 month prior screen visit Subjects druginduced SLE , oppose idiopathic SLE Subjects severe , unstable and/or progressive Central nervous system ( CNS ) lupus Subjects autoimmune disease SLE main diagnosis ( e.g . ; Rheumatoid arthritis ( RA ) , Multiple Sclerosis [ MS ] ) Subjects receive treatment cyclophosphamide within 3 month randomization ( Day 1 ) . Subjects receive treatment rituximab &lt; 6 month prior screen visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>